Insulin resistance has been shown to have an association with polycystic ovary syndrome (PCOS). This study was designed to evaluate the potential role of adiponectin, which is linked with insulin resistance, in the etiology of PCOS and its relationship to obesity.
Methods:
This case–control study consisted of 103 newly diagnosed PCOS cases and 73 female controls seen at a referral university hospital in Zanjan, Iran. Serum adiponectin, insulin, plasma fasting glucose, and lipid levels were measured. The homeostasis model assessment index was used to determine the level of insulin resistance. Women were classified as follows: Group I (normal nonlean women); group II (normal lean women); group III (nonlean women with PCOS); and group IV (lean women with PCOS)
Results:
Adiponectin levels were decreased in women with PCOS (8.4 ± 2.7 ng/mL vs. 13.6 ± 5 ng/mL in the control group, P < 0.001). There was no significant difference between the adiponectin concentrations of women in group III and that in group IV (8.1 ± 2.8 ng/mL vs. 9.2 ± 2.6 ng/mL, respectively, P = 0.1). Adiponectin levels were significantly lower in group I compared with group II. A weak but significant negative correlation was found between adiponectin and insulin levels in all the subjects. Multiple regression analyses showed that the presence of PCOS was the only significant determinant of serum adiponectin levels.
Conclusions:
Adiponectin levels were reduced in all the women with PCOS. There seemed to be an interaction between adiponectin and PCOS pathogenesis that was independent of body mass index.
Get full access to this article
View all access options for this article.
References
1.
AhimaRS, FlierJS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab, 2000; 11:327–332.
SchererPE, WilliamsS, FoglianoM, BaldiniG, LodishHF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995; 270:26746–26749.
BergAH, CombsTP, DuX, BrownleeM, SchererPE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med, 2001; 7:947–953.
7.
HottaK, FunahashiT, BodkinNL, OrtmeyerHK, AritaY, HansenBC, MatzuzawaY. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression of type 2 diabetes in rhesus monkeys. Diabetes, 2001; 50:1126–1133.
WeyerC, FunahashiT, TanakaS, HottaK, MatzuzawaY, PratleyRE. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001; 86:1930–1935.
10.
PhilipsSA, CiaraldiTP, KongAP, BandukwalaR, ArodaV, CarterL, BaxiS, MudaliarSR, HenryRR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes, 2003; 52:667–674.
11.
HottaK, FunahashiT, AritaY, TakahashiM, MatsudaM, OkamotoY, IwahashiH, KuriyamaH, OuchiN, MaedaK, NishidaM, KiharaS, SakaiN, NakajimaT, HasegawaK, MuraguchiM, OhmotoY, NakamuraT, YamashitaS, HanafusaT, MatsuzawaY. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 2000; 20:1595–1599.
12.
LindsayRS, FunahashiT, HansonRL, MatsuzawaY, TanakaS, TataranniPA, KnowlerWC, KrakoffJ. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 2002; 360:57–58.
13.
ZawadskiJK, DunaifA. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In DunaifA, GivensJR, HaseltineFP, MerriamGE. (eds.). Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Boston: Blackwell Scientific Publications, 1992:377.
14.
PanidisD, RoussoD, MatalliotakisI, KourtisA, StamatopoulosP, KoumantakisE. The influence of long-term administration of conjugated estrogens and antiandrogens to serum leptin levels in women with polycystic ovary syndrome. Gynecol Endocrinol, 2000; 14:169–172.
15.
CostelloMF, EdenJA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril, 2003; 79:1–13.
16.
FranksS. Polycystic ovary syndrome. N Engl J Med, 1995; 333:853–861.
AdashiEY, ResnickCE, D’ErcoleAJ, SvobodaME, VanWyk JJ. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev, 1985; 6:400–420.
19.
EhrmannDA, BarnesRB, RosenfieldRL, CavaghanMK, ImperialJ. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 1999; 22:141–146.
XuA, ChanKW, HooRL, WangY, TanKC, ZhangJ, ChenB, LamMC, TseC, CooperGJ, LamKS. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem, 2005; 280:18073–18080.
22.
BroekmansFJ, KnauffEAH, ValkenburgO, LavenJS, EijkemansMJ, FauserBCJM. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG, 2006; 113:1210–1217.
23.
MeshkaniR, TaghikhanM, LarijaniB, KhatamiS, KhoshbinE and AdeliKH. The relationship between homeostasis model assessment and cardiovascular risk factors in Iranian subjects with normal fasting glucose and normal glucose tolerance. Clinica Chimica Acta, 2006; 371:169–175.
24.
DunaifA. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev1997; 18:774–800.
PhilipsSA, CiaraldiTP, KongAPSet al.Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes, 2003; 52:667–674.
27.
LegroRS, FinegoodD, DunaifA. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 1998; 83:2694–2698.
28.
RadziuckJ. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab, 2000; 85:4426–4433.
29.
OrioJR, PalombaS, CascellaT, OrioFJr, PalombaS, CascellaT, MilanG, MioniR, PaganoC, ZulloF, ColaoA, LombardiG, VettorR. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2003; 88:2619–2623.
30.
GulcelikNE, AralY, SerterR, DemirY, CulhaC. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol, 2006; 22:511–515.
31.
PanidisD, KourtisA, FarmakiotisD, MouslechT, RoussoD, KoliakosG. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod, 2003; 18:1790–1796.
32.
OrioFJr, PalombaS, ZulloF, ColaoA, LombardiG. Are serum adiponectin levels really reduced in obese women with polycystic ovary syndrome?. Hum Reprod, 2004; 19:215.
33.
WangY, YuP. Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2009; 34:72–75.
34.
LiX, LinJF. Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi, 2005; 85:3266–3271.
35.
ArdawiMS, RouziAA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril, 2005; 83:1708–1716.
36.
YilmazM, BukanN, DemirciH, OztürkC, KanE, AyvazG, ArslanM. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol, 2009; 25:246–252.
37.
GlintborgD, FrystykJ, HojlundK, AndersenKK, HenriksenJE, HermannAP, HagenC, FlyvbjergA, AndersenM. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol, 2008; 68:165–174.
GonzálezF, RoteNS, MiniumJ, KirwanJP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism, 2009; 58:954–962.
40.
GonzalezF, ThusuK, Abdel-RahmanE, PrabhalaA, TomaniM, DandonaP. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism, 1999; 48:437–441.
41.
LewandowskiKC, SzoslandK, O’CallaghanC, TanBK, RandevaHS, LewinskiA. Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab, 2005; 85:61–69.
